Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
36.88
+2.57 (7.49%)
At close: Aug 13, 2025, 4:00 PM
37.04
+0.16 (0.43%)
After-hours: Aug 13, 2025, 6:24 PM EDT
Cytokinetics Stock Forecast
Stock Price Forecast
According to 12 professional analysts, the 12-month price target for Cytokinetics stock ranges from a low of $41 to a high of $120. The average analyst price target of $71.58 forecasts a 94.09% increase in the stock price over the next year.
Price Target: $71.58 (+94.09%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Cytokinetics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 4 | 4 | 4 |
| Buy | 9 | 10 | 7 | 7 | 7 | 7 |
| Hold | 2 | 2 | 3 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 18 | 16 | 14 | 14 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $80 → $77 | Strong Buy | Maintains | $80 → $77 | +108.79% | Aug 8, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $71 → $53 | Buy | Maintains | $71 → $53 | +43.71% | Jun 9, 2025 |
| Mizuho | Mizuho | Buy Maintains $103 → $84 | Buy | Maintains | $103 → $84 | +127.77% | May 29, 2025 |
| Needham | Needham | Strong Buy Reiterates $72 | Strong Buy | Reiterates | $72 | +95.23% | May 14, 2025 |
| Barclays | Barclays | Buy Maintains $55 → $53 | Buy | Maintains | $55 → $53 | +43.71% | May 8, 2025 |
Financial Forecast
Revenue This Year
23.48M
from 18.47M
Increased by 27.08%
Revenue Next Year
176.56M
from 23.48M
Increased by 652.09%
EPS This Year
-5.61
from -5.26
EPS Next Year
-5.13
from -5.61
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 93.2M | 415.8M | 742.0M | ||
| Avg | 23.5M | 176.6M | 427.8M | ||
| Low | 1.5M | 47.0M | 213.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 404.7% | 1,671.2% | 320.3% | ||
| Avg | 27.1% | 652.1% | 142.3% | ||
| Low | -91.6% | 100.4% | 20.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.28 | -3.02 | -0.53 | ||
| Avg | -5.61 | -5.13 | -3.30 | ||
| Low | -6.47 | -6.75 | -5.48 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.